Bolt Biotherapeutics, Inc. Research and Development Expense
Bolt Biotherapeutics, Inc. (BOLT) reported Research and Development Expense of $5.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $5.15M, a 31.33% decline year-over-year.
- Bolt Biotherapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $4.83M, a 49.23% decline year-over-year.
- Bolt Biotherapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $4.99M, a 57.45% decline year-over-year.
- Bolt Biotherapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $6.54M, a 52.59% decline year-over-year.
- Bolt Biotherapeutics, Inc. research and development expense for fiscal 2025 was $28.53M, a 50.35% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. research and development expense for fiscal 2024 was $57.47M, a 6.62% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. research and development expense for fiscal 2023 was $61.54M, a 15.84% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. research and development expense for fiscal 2022 was $73.12M, a 3.35% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.15M 10-Q · filed 2026-08-11 | $9.98M 10-Q · filed 2026-08-11 | $14.97M derived: sum of 3 quarters · filed 2026-08-11 | $21.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.83M 10-Q · filed 2026-05-12 | $9.82M derived: sum of 2 quarters · filed 2026-05-12 | $16.35M derived: sum of 3 quarters · filed 2026-05-12 | $23.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.52M derived: sum of 2 quarters · filed 2026-03-12 | $19.02M derived: sum of 3 quarters · filed 2026-08-11 | $28.53M 10-K · filed 2026-03-12 |
| 2025-09-30 | $6.54M 10-Q · filed 2025-11-12 | $14.03M derived: sum of 2 quarters · filed 2026-08-11 | $23.55M 10-Q · filed 2025-11-12 | $35.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $7.50M 10-Q · filed 2026-08-11 | $17.01M 10-Q · filed 2026-08-11 | $28.73M derived: sum of 3 quarters · filed 2026-08-11 | $42.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $9.51M 10-Q · filed 2026-05-12 | $21.23M derived: sum of 2 quarters · filed 2026-05-12 | $35.02M derived: sum of 3 quarters · filed 2026-05-12 | $50.45M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $11.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $25.51M derived: sum of 2 quarters · filed 2026-03-12 | $40.94M derived: sum of 3 quarters · filed 2026-03-12 | $57.47M 10-K · filed 2026-03-12 |
| 2024-09-30 | $13.79M 10-Q · filed 2025-11-12 | $29.22M derived: sum of 2 quarters · filed 2025-11-12 | $45.75M 10-Q · filed 2025-11-12 | $62.07M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $15.43M 10-Q · filed 2025-08-14 | $31.96M 10-Q · filed 2025-08-14 | $48.28M derived: sum of 3 quarters · filed 2025-08-14 | $63.23M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $16.53M 10-Q · filed 2025-05-12 | $32.85M derived: sum of 2 quarters · filed 2025-05-12 | $47.80M derived: sum of 3 quarters · filed 2025-05-12 | $63.45M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $16.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $31.27M derived: sum of 2 quarters · filed 2025-03-24 | $46.92M derived: sum of 3 quarters · filed 2025-03-24 | $61.54M 10-K · filed 2025-03-24 |
| 2023-09-30 | $14.95M 10-Q · filed 2024-11-12 | $30.59M derived: sum of 2 quarters · filed 2024-11-12 | $45.22M 10-Q · filed 2024-11-12 | $62.06M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $15.64M 10-Q · filed 2024-08-13 | $30.27M 10-Q · filed 2024-08-13 | $47.11M derived: sum of 3 quarters · filed 2024-08-13 | $66.09M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $14.63M 10-Q · filed 2024-05-14 | $31.47M derived: sum of 2 quarters · filed 2024-05-14 | $50.44M derived: sum of 3 quarters · filed 2024-05-14 | $69.36M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $16.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $35.82M derived: sum of 2 quarters · filed 2024-03-21 | $54.74M derived: sum of 3 quarters · filed 2024-03-21 | $73.12M 10-K · filed 2024-03-21 |
| 2022-09-30 | $18.97M 10-Q · filed 2023-11-09 | $37.89M derived: sum of 2 quarters · filed 2023-11-09 | $56.28M 10-Q · filed 2023-11-09 | $78.76M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $18.92M 10-Q · filed 2023-08-07 | $37.30M 10-Q · filed 2023-08-07 | $59.79M derived: sum of 3 quarters · filed 2023-08-07 | $79.13M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $18.39M 10-Q · filed 2023-05-11 | $40.87M derived: sum of 2 quarters · filed 2023-05-11 | $60.21M derived: sum of 3 quarters · filed 2023-05-11 | $79.91M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $22.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $41.82M derived: sum of 2 quarters · filed 2023-03-29 | $61.53M derived: sum of 3 quarters · filed 2023-03-29 | $75.66M 10-K · filed 2023-03-29 |
| 2021-09-30 | $19.34M 10-Q · filed 2022-11-10 | $39.04M derived: sum of 2 quarters · filed 2022-11-10 | $53.17M 10-Q · filed 2022-11-10 | $68.03M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $19.71M 10-Q · filed 2022-08-10 | $33.83M 10-Q · filed 2022-08-10 | $48.70M derived: sum of 3 quarters · filed 2022-08-10 | $58.24M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $14.13M 10-Q · filed 2022-05-12 | $28.99M derived: sum of 2 quarters · filed 2022-05-12 | $38.53M derived: sum of 3 quarters · filed 2022-05-12 | $47.70M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $24.40M derived: sum of 2 quarters · filed 2022-03-30 | $33.57M derived: sum of 3 quarters · filed 2022-03-30 | $40.36M 10-K · filed 2022-03-30 |
| 2020-09-30 | $9.54M 10-Q · filed 2021-11-09 | $18.71M derived: sum of 2 quarters · filed 2021-11-09 | $25.49M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $9.17M 10-Q · filed 2021-08-12 | $15.95M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $6.79M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |